Search Results for:Carl O'Donnell

Horizons Ventures-backed video conferencing firm Zoom draws IPO roadmap

Zoom is aiming to be valued in the IPO at several billion dollars more than the $1 billion valuation it achieved in its most recent funding round in 2017, when it received $100 million from venture capital firm Sequoia.


Musk’s Tesla buyout plan – No formal offer, no firm deals with advisers

Three members of Tesla’s board will now weigh whether it is advisable – or even feasible – to pursue what could be the biggest-ever go-private deal, and they are doing so before receiving a formal proposal from the CEO.


Tesla board seeks more information on Musk’s go-private plan

The board expects to make a decision on whether to launch a formal review of Musk’s proposal in the coming days and is speaking to investment bankers about hiring financial advisers to assist it in its review in such scenario.


SoftBank’s Son says to continue with deals despite trade jitters

Son is optimistic that U.S. President Donald Trump’s escalation of trade disputes and heightened scrutiny of foreign investments would not affect the Japanese firm’s prolific deal-making.


SoftBank CEO running out of time to clinch Sprint-T-Mobile merger

This is the companies’ third attempt to clinch a deal in the last four years.


US drugstore chain CVS Health to acquire insurer Aetna for $69b in year’s largest acquisition

The deal comes after Aetna’s $37 billion plan to acquire smaller U.S. health insurance peer Humana Inc  was blocked in January by a U.S. federal judge over antitrust concerns.


US pension fund CalPERS mulls changes in PE investing strategy

The move could result in slashing payments to fund managers


GIC, Abu Dhabi fund in talks to buy stake in US clinical trials firm

A deal could value the entire company at over $9 billion.


Starwood in talks on raising initial bid for Milestone REIT

The earlier agreed deal value was $1.3 billion.


Pfizer’s Medivation buy seen prescribing more biotech M&A

Pfizer Inc, beating out numerous other bidders, said it agreed to buy U.S. cancer drug company Medivation Inc for $14 billion in cash, adding its blockbuster prostate cancer drug Xtandi to the company’s growing oncology roster. Medivation shares jumped nearly 20 percent to close at $80.42, just shy of the offer… Read more »